Результаты поиска

Targeting fibrosis, mechanisms and cilinical trials.

Fibrosis is characterized by the excessive extracellular matrix deposition due to dysregulated wound and connective tissue repair response. Multiple organs can develop fibrosis, including the liver, kidney, heart, and lung. Fibrosis such as liver cirrhosis, idiopathic pulmonary fibrosis, and cystic fibrosis caused substantial disease burden. Persistent abnormal activation of myofibroblasts mediated by various signals, such as transforming growth factor, platelet-derived growth factor, and fibroblast growh factor, has been recongized as a major event in the occurrence and progression of fibrosi

Совпадение в полном тексте источника
… Semaglutide Semaglutide is a GLP-1 receptor agonist and has been approved for T2DM therapy. In a 72-week phase 2 trial, NASH patients with liver fibrosis of stage F1, F2, or F3 received placebo, or semaglutide at 0.1 mg, 0.2 mg, or 0.4 mg. … The percentage of patients who achieved NASH improvement without worsening fibrosis was 40%, 36% and 59% in the 0.1 mg semaglutide group, 0.2 mg semaglutide group and 0.4 mg semaglutide group, respectively, and 17% in the placebo group. …

AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review.

DESCRIPTION: Steatotic liver disease (SLD) is the leading cause of chronic liver disease and liver-related mortality in the United States. T … States Food and Drug Administration-approved treatments for noncirrhotic MASLD (ie, resmetiron and semaglutide) has not been formally studied in MetALD. However, preliminary data suggests that glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists may reduce alcohol cravings and consumption and improve hepatic parameters. …

Перекресток между диабетом и болезнью Альцгеймера: Молекулярная перспектива.

Общемировая распространенность видов 2 Заболевание сахарным диабетом (T2DM) и болезнью Альцгеймера (AD) значительно возрастает в зависимости от возраста. Растущие данные подтверждают концептуализацию АД как типа 3 диабет, термин, предлагаемый для описания метаболического заболевания, вызванного главным образом поврежденной инсулиновой сигнализацией и инсулиновой резистентностью в мозге. В рамках этого обзора изучаются общие молекулярные механизмы, лежащие в основе как T2DM, так и AD, включая хроническую нейроинфламму, окислительный стресс, митохондриальную дисфункцию и поврежденный метаболизм

Совпадение в полном тексте источника
… Human: Ph2b RCT (liraglutide, ELAD), Ph3 RCTs (semaglutide, EVOKE/EVOKE+); observational cohorts Memory, tau, amyloid, TNF‐α; cognitive decline, brain atrophy, progression (CDR‐SB), biomarkers Preclinical: ↑ memory, ↓ tau, ↓ amyloid, ↓ TNF‐α. … Semaglutide Ph3: no slowing of progression. …

Повторное регулирование веса после трансплантации печени с использованием глюкагонового пептида one агонисты желудочно-кишечного ингибитора полипептида.

Ожирение является сложным осложнением, с которым сталкиваются многие реципиенты, реципиенты трансплантации печени. Пересадка печени является единственной жизненно важной процедурой во многих конечных болезнях печени, однако лежащая в ее основе патология, помимо некоторых иммунодепрессивных режимов, может ухудшить метаболическое состояние многих пациентов. Для получения благоприятного прогноза и улучшения качества жизни необходим комплексный план управления, направленный на предотвращение дальнейших осложнений, связанных с метаболической дисфункцией, ситуативной болезнью печени, хронической дис

Совпадение в полном тексте источника
… Another study examined the real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of 285 Italian type 2 diabetic patients. … Discontinuation data revealed that a total of 39 out of 258 patients (15.1%) receiving at least one dose of once weekly semaglutide withdrew from treatment. …

Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.

Parkinson's disease (PD) significantly affects patients' quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared to the traditional drug development strategy. This review aimed to collect evidence of drugs proposed as candidates to be reused in PD and identify those with the potential to be reformulated into nanocarriers to optimize future repositioning trials. We conducted a detailed search in PubMed, Web of Science,

Совпадение в полном тексте источника
… Semaglutide This drug is one of those recently proposed for reuse in PD that has reached clinical trials; it is currently in a trial with the ClinicalTrials.gov identifier: NCT03659682 . … Semaglutide is neuroprotective and reduces α-synuclein levels in the chronic MPTP mouse model of Parkinson’s disease. J Parkinsons Dis. 2019;9(1):157–171. doi: 10.3233/JPD-181503. 11. Schaffner A, Li X, Gomez-Llorente Y, Leandrou E, Memou A, Clemente N, et al. …

Obesity and Cancer: Mechanisms, Epidemiological Evidence, and Potential Risk Reduction.

Obesity promotes carcinogenesis through interlocking metabolic, inflammatory, immune, and hormonal pathways. We narratively synthesize recent meta-analyses and selected cohort studies that examine adiposity-principally body mass index (BMI) and waist circumference-in relation to cancer incidence. Across the 13 cancers designated by the U.S. National Cancer Institute as obesity-associated, risk elevations are generally consistent, though magnitudes vary by histology (e.g., esophageal adenocarcinoma vs. squamous cell carcinoma), anatomic subsite (gastric cardia vs. non-cardia), sex or menopausal

Совпадение в полном тексте источника
… A retrospective United States cohort study reported that GLP-1 RA (liraglutide, semaglutide, and dulaglutide) use was associated with a significantly reduced risk of several cancers: gastrointestinal cancer (HR, 0.67; 95% CI, 0.59 to 0.75), skin cancer (HR, 0.62; 95% CI, 0.55 to 0.70), breast cancer … genital cancers (HR, 0.61; 95% CI, 0.53 to 0.71), prostate cancer (HR, 0.68; 95% CI, 0.58 to 0.80), and lymphoid/hematopoietic cancers (HR, 0.69; 95% CI, 0.60 to 0.80). 88 In subgroup analyses of individual GLP-1 RA agents, the risk of gastrointestinal cancers was lower among patients treated with semaglutide …

Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk.

The study aimed to perform a systematic review and meta-analysis of the evidence for the prevention of future cancers following bariatric surgery. A systematic literature search of the Cochrane Library, Embase, Scopus, Web of Science and PubMed databases (2007-2023), Google Scholar and grey literature was conducted. A meta-analysis was performed using the inverse variance method and random effects model. Thirty-two studies involving patients with obesity who received bariatric surgery and control patients who were managed with conventional treatment were included. The meta-analysis suggested b

Совпадение в полном тексте источника
… A similar result was achieved with once-weekly s/c semaglutide (2.4 mg/week) in the STEP 6 RCT involving obese Japanese and South Korean patients (BMI ≥ 27 kg/m 2 ) of 13.2% TBW loss at 68 weeks [ 128 ]. … The steepest weight regain after the cessation of semaglutide occurred in patients who had previously lost >20% of their TBW [ 129 ], which reflects the persistence of neurohormonal and behavioural pathways in patients with obesity [ 24 ]. …

Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management.

The first part of this review highlighted the evolving landscape of atherosclerosis, noting emerging cardiometabolic risk factors, the growing impact of exposomes, and social determinants of health. The prominent role of atherosclerosis in the bidirectional relationship between cardiovascular disease and cancer was also discussed. In this second part, we examine the complex interplay between multimorbid cardio-oncologic patients, cardiometabolic risk factors, and the harmful environments that lend a "syndemic" nature to these chronic diseases. We summarize management strategies targeting disor

Совпадение в полном тексте источника
… Liraglutide and Semaglutide have also been approved for obesity treatment after the SCALE and the STEP programs [ 225 , 226 , 227 , 228 ]. GLP-1 RAs may have a potential role in reducing obesity-related cancer risk [ 229 ]. … Notably, Semaglutide carries a boxed warning from the Food and Drug Administration (FDA) regarding the potential risk of thyroid C-cell cancer, specifically medullary thyroid carcinoma [ 233 ]; this increased risk has not been observed with liraglutide. …

RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges.

G protein-coupled receptors (GPCRs) are the major targets of existing drugs for a plethora of human diseases and dominate the pharmaceutical market. However, over 50% of the GPCRs remain undruggable. To pursue a breakthrough and overcome this situation, there is significant clinical research for developing RNA-based drugs specifically targeting GPCRs, but none has been approved so far. RNA therapeutics represent a unique and promising approach to selectively targeting previously undruggable targets, including undruggable GPCRs. However, the development of RNA therapeutics faces significant cha

Совпадение в полном тексте источника
… For example, selepressin is a novel selective vasopressin V1a receptor agonist with a longer plasma half-life because of the introduction of non-natural amino acids at the proteolysis site. 46 , 47 Semaglutide is a GLP-1 receptor agonist with a half-life of 168 h that is approved for the treatment of … Semaglutide contains a free fatty acid linker that allows the molecule to form a non-covalent reversible interaction with serum albumin, which significantly enhances its half-life. 31 Furthermore, tirzepatide (Mounjaro), a dual GIP/GLP-1, is a key regulator of insulin secretion and has also been used …

Balancing Innovation and Access: Insights from AIM's Fair Pricing Model and Its Current and Future Applications.

OBJECTIVE: Access to affordable medicines is a cornerstone of equitable healthcare, yet escalating drug prices increasingly strain national healthcare systems. Cost-based pricing can be a useful complement to value-based pricing, provided that relevant variables are considered. METHODS: We applied the International Association of Mutual Benefit Societies (AIM) Fair Pricing Model to ten market-protected medicines authorized by the European Medicines Agency between 2015 and 2018, covering oncology, rare diseases, and chronic conditions. Analyses were conducted across six European countries-Belg

Совпадение в полном тексте источника
… Palbociclib | Cancer | 24.72/100,000 (I) | 2 | Chemical (50) | No | 9 months | 10% (life-threatening disease 5% and pfs gain of at least 6 months) Triumeq® | Dolutegravir/abacavir/lamivudine | Chronic | Number in Europe = 866,899 | 2 | Chemical (50) | No | 120 months | 5% (life-threatening) Ozempic® | Semaglutide … For the treatment of a high prevalence chronic condition, which is the case for semaglutide, the authors considered that the default lump sum did not reflect the actual low production costs associated with major volumes and applied a fivefold reduced lump sum, following AIM recommendations in the accompanying …

17th Конгресс ЕВНОС: Милан, Италия, 4–6 Июнь, 2026 года

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… When NAION is not NAION: Bilateral optic disc edema during semaglutide therapy Agata Anna Wykrota Department of Ophthalmology, San Maurizio Hospital, Bolzano, Italy Introduction : Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide, are increasingly prescribed for type … This case adds to emerging data suggesting that semaglutide may be associated with a NAION-like presentation driven by non-ischemic mechanisms, such as transient axoplasmic flow disturbance or altered intracranial pressure regulation. …

Obesity as a Multifactorial Chronic Disease: Molecular Mechanisms, Systemic Impact, and Emerging Digital Interventions.

Obesity is a multifactorial chronic disease resulting from complex genetic, molecular, environmental, and behavioral interactions. Its prevalence rises worldwide, affecting cardiovascular, metabolic, oncological, hepatic, respiratory, and skeletal health. Beyond caloric excess, genetic predisposition, epigenetic modifications, gut microbiota dysbiosis, endocrine-disrupting agents, circadian misalignment, and intergenerational and prenatal influences are critical determinants of obesity risk. Core pathophysiological mechanisms include insulin resistance, dyslipidemia, chronic low-grade inflamma

Совпадение в полном тексте источника
… Like other GLP-1 receptor agonists, semaglutide’s main side effects are gastrointestinal, typically mild to moderate, and improve over time [ 113 ]. … In 2021, semaglutide 2.4 mg weekly was added, showing nearly double the weight loss seen with earlier treatments, marking a major advance in obesity therapy. The later approval of oral semaglutide further expanded options for patients, particularly those with T2DM seeking non-injectable treatments. …

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology.

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown. This statement underscores the imperative need to include HFpEF in the cardiotoxicities identified during or after anticancer treatments. It also highlights the prognostic value of pre-existing HFpEF for periprocedural and cardiotoxicity risk and it discusses the challenges in the diagnosis and treatment of HFpEF in cancer patients. It also explores the aetiologic role of anticancer therapies (chemotherapy, targe

Совпадение в полном тексте источника
… Since these guidelines, the publication of four landmark randomized controlled trials (RCTs) with finerenone, semaglutide and tirzepatide provided significant new data for the management of patients with HFpEF. … Semaglutide in patients with heart failure with preserved ejection fraction and obesity . …

Пригодны ли глюкагоны-подобно Пептиды-1 для агонистов-рецепторов для вторичной истерии?

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… In the SUSTAIN-6 trial, semaglutide reduced the incidence of nonfatal stroke by approximately 39% ( p =0.04), providing evidence that GLP-1RAs confer cerebrovascular protection. 8 Similar findings were subsequently obtained in the REWIND trial, in which dulaglutide significantly reduced the incidence …

Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer.

Insulin resistance (IR) describes impaired hormone signaling that triggers compensatory homeostatic responses resulting in hyperinsulinemia, increased accumulation of fatty substrates, lipotoxicity, oxidative stress, inflammation, cell death and fibrosis in target tissues. These processes ultimately lead to organ dysfunction and predispose certain individuals to various types of cancer. In this context, we will review the molecular pathogenesis and clinical significance of IR, its role in 'metaflammation', and the damage caused by IR in the pancreas, cardiovascular system, liver, and kidneys.

Совпадение в полном тексте источника
… Semaglutide is available for weekly subcutaneous administration or daily oral administration [ 180 ]. … The most common adverse events are generally transient mild-to-moderate gastrointestinal complaints; hypoglycemia is more common without lifestyle intervention and weight regain will often follow semaglutide withdrawal [ 179 ]. …

Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management.

BackgroundObesity or excess body fat is a major global health challenge that has not only been associated with diabetes mellitus and cardiovascular disease but is also a major risk factor for the development of and mortality related to a subgroup of cancer. This review focuses on epidemiology, the relationship between obesity and the risk associated with the development and recurrence of cancer and the management of obesity.MethodsA literature search using PubMed and Google Scholar was performed and the keywords 'obesity' and cancer' were used. The search was limited to research papers publish

Совпадение в полном тексте источника
… The most important of these are glucagon-like peptide-1 (GLP-1) analogue liraglutide and semaglutide. … Semaglutide is available as a weekly injection [ 30 ]. A handful of preclinical studies suggest their association with thyroid and pancreatic cancer [ 151 , 152 ]. …

Конвергенция глобальных эпидемий: диабет как модулятор нейродегенеративных и нейро-воспалительных расстройств.

Диабет меллитус (ДМ) и неврологические расстройства быстро совпадают с глобальным бременем на здоровье, обусловленным старением населения, растущей распространенностью метаболического синдрома, а также ограниченностью возможностей раннего обнаружения и коррекции заболеваний для многих неврологических синдромов. Помимо своей устоявшейся роли в периферической нейропатии, связанной с диабетом, DM все чаще используется в качестве изменяющего фактора риска, фенотипа и прогнозирования широкого спектра заболеваний центральной и периферической нервной системы. В ходе этого обзора мы обобщаем текущие э

Совпадение в полном тексте источника
… and α-synuclein; enhances mitochondrial function; suppresses neuroinflammation +++ Broad neuroprotection in AD, PD, and MS models; GLP-1R expressed in CNS ++ Reduced all-cause dementia risk (OR 0.55, 95% CI 0.35–0.86 in RCT meta-analysis); lower dementia incidence vs. comparators +/− Evoke/Evoke+ (semaglutide … In late 2025, the evoke and evoke+ Phase III randomized controlled trials (RCTs) showed that among patients with early-stage symptomatic AD, semaglutide failed to distinguish itself from placebo in its effects on AD progression ( 136 ). This led these trials to be discontinued. …

Irish Endocrine Society 44th Annual Meeting.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients.

Anthracyclines remain a cornerstone of cancer therapy but are associated with a significant risk of cardiotoxicity, which can lead to overt heart failure. The risk is modulated by cumulative dose, pre-existing cardiovascular disease, and patient-specific factors. As cancer survival improves, the long-term cardiovascular consequences of anthracycline exposure have become a growing concern, underscoring the need for effective preventive strategies. This narrative review examines lifestyle and pharmacological interventions aimed at mitigating anthracycline-induced cardiotoxicity. Evidence suggest

Совпадение в полном тексте источника
… Preclinical studies indicate that semaglutide ameliorates doxorubicin-induced cardiotoxicity by reducing mitochondrial dysfunction via inhibition of BNIP3 signaling, a key mediator of mitophagy [ 111 ]. … Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction Redox. Biol. 2024 72 103129 10.1016/j.redox.2024.103129 38574433 PMC11000183 112. HamaSalih R.M. …

A Standardized Method for Vertical Sleeve Gastrectomy Bariatric Surgery Investigations in Cancer.

Obesity is a global epidemic that has affected the lives of over 14% of adults worldwide and over a third of Americans. Obesity is associated with the increased risk of thirteen obesity-associated cancers and poor cancer outcomes. Bariatric surgery is the most effective method of sustained weight loss and has been steadily increasing in clinical use over the past 4 decades. Importantly, bariatric surgery is established to decrease cancer risk. Vertical sleeve gastrectomy (VSG) is currently the most common bariatric surgery procedure. To evaluate underlying mechanisms of bariatric associated ca

Совпадение в полном тексте источника
… The role of pharmaceuticals such as semaglutide and other GLP-1 receptor agonists is of great interest because it is unknown if medical weight loss will achieve the same cancer-preventive benefits as observed after weight loss by bariatric surgery. … We have published that in murine models, weight loss by GLP-1 receptor agonist semaglutide (Ozempic or Wegovy) compared to a novel triple receptor agonist retatrutide reduced both tumor onset and progression in pancreatic and lung cancer ( Marathe et al., 2025 ). …